Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Yasmin 20 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Yasmin 20 | DRUG | Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral) |
| Mercilon | DRUG | Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral) |
| Yasmin | DRUG | 30 µg ethinylestradiol, 3mg drospirenone |
| Marvelon | DRUG | 30 µg ethinylestradiol, 150 µg desogestrel |
Inclusion Criteria: * Healthy female volunteer aged 18-35, * Smokers 18-30 Exclusion Criteria: * Contraindications for using hormonal contraceptives
Yasmin is a combined oral contraceptive used for contraception in women. It is being studied in Phase 3 clinical trials for healthy volunteers and for contraception, with trials conducted in China and other countries. The drug is developed by Bayer AG.
Yasmin is developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The drug is a small molecule oral contraceptive currently in Phase 3 clinical development.
Yasmin is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All three clinical trials for Yasmin are Phase 3 trials, and all have been completed.
Yasmin has been studied in three Phase 3 clinical trials. NCT00185419 compared Yasmin to Marvelon in Chinese women requiring contraception. NCT00367276 evaluated the effect of Yasmin on quality of life. NCT00624130 compared Yasmin 20 to Mercilon in healthy female volunteers.
Yasmin is not the same as Marvelon or Mercilon. Clinical trials have compared Yasmin to these other oral contraceptives, but they are distinct products. Yasmin contains drospirenone and ethinyl estradiol, while Marvelon and Mercilon contain different progestins.